Atossa Therapeutics (ATOS) said Wednesday it has completed enrollment in part B of its phase 1/2a trial of drug candidate AT-H201 in Australia.
AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for "long-haul" patients with post-infection pulmonary disease, the clinical-stage drugmaker said. The phase 1/2a trial will enroll 60 healthy participants and moderately-ill hospitalized COVID-19 patients and will be carried out in four parts.
Atossa Therapeutics said it completed in vitro testing of AT-H201 in May 2020. Data showed that the components of AT-H201 inhibit COVID-19 infectivity of Vero cells, a type of cell that is being used to study infectivity of the coronavirus.
AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for "long-haul" patients with post-infection pulmonary disease, the clinical-stage drugmaker said. The phase 1/2a trial will enroll 60 healthy participants and moderately-ill hospitalized COVID-19 patients and will be carried out in four parts.
Atossa Therapeutics said it completed in vitro testing of AT-H201 in May 2020. Data showed that the components of AT-H201 inhibit COVID-19 infectivity of Vero cells, a type of cell that is being used to study infectivity of the coronavirus.